Minerva ginecologica 2009-10-01

[Nomegestrol acetate: clinical pharmacology].

S Lello

Index: Minerva Ginecol. 61(5) , 459-63, (2009)

Full Text: HTML

Abstract

Progestogens are used in clinical practice in some conditions. Their effects depend on their chemical structure, pharmacokinetics, pharmacodynamics, with important differences among various progestogens. Generally, progestins are classified according to their parent molecule, of which often they keep some features. Derivatives of 19-nor-progesterone are characterized by high selectivity of action on progestin receptor. In particular, nomegestrol acetate (NomAc) shows an important progestational potency, neutral gluco-lipid profile, and antigonadotropic activity. It is used for treating menstrual cycle disorders and for hormone replacement therapy in menopause in association with an estrogen. In future, thanks to its antigonadotropic activity, NomAc will be used in estroprogestin combinations in fertile women, thus taking advantage of its tolerability profile and obtaining numerous non-contraceptive benefits as well.

Related Compounds

  • Nomegestrol acetat...

Related Articles:

Changing convention in combination oral contraceptives: estradiol and nomegestrol acetate in a monophasic 24/4 regimen.

2013-07-01

[J. Fam. Plann. Reprod. Health Care 39(3) , 211-6, (2013)]

A new contraceptive pill containing 17β-estradiol and nomegestrol acetate.

2013-01-01

[Womens. Health (Lond. Engl.) 9(1) , 13-23, (2013)]

The “newer” progestogens and postmenopausal hormone therapy (HRT)

2014-07-01

[J. Steroid Biochem. Mol. Biol. 142 , 48-51, (2014)]

Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17β-estradiol (NOMAC/E2): a double-blind, randomized study.

2011-06-01

[Hum. Reprod. 26(6) , 1338-47, (2011)]

Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: a double-blind, randomised, dose-finding pilot study.

2011-04-01

[Eur. J. Contracept. Reprod. Health Care 16(2) , 76-84, (2011)]

More Articles...